July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
iPSC-RPE cells derived from atrophic age-related macular degeneration patients have a typical disease phenotype
Author Affiliations & Notes
  • Audrey Voisin
    INSERM U1084 LNEC, Poitiers, France
    University hospital of Poitiers, France
  • Alexandra Plancheron
    INSERM UMR861, France
    CECS/I-Stem, France
  • Christelle Monville
    INSERM UMR861, France
    UEVE-ParisSaclay UMR861, France
  • Anaïs Balbous
    INSERM U1084 LNEC, Poitiers, France
    University hospital of Poitiers, France
  • Afsaneh Gaillard
    INSERM U1084 LNEC, Poitiers, France
    University of Poitiers, France
  • Nicolas Leveziel
    INSERM U1084 LNEC, Poitiers, France
    University hospital of Poitiers, France
  • Footnotes
    Commercial Relationships   Audrey Voisin, None; Alexandra Plancheron, None; Christelle Monville, None; Anaïs Balbous, None; Afsaneh Gaillard, None; Nicolas Leveziel, None
  • Footnotes
    Support  Poitou Charentes Region, Hospital University of Poitiers, Novartis
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1224. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Audrey Voisin, Alexandra Plancheron, Christelle Monville, Anaïs Balbous, Afsaneh Gaillard, Nicolas Leveziel; iPSC-RPE cells derived from atrophic age-related macular degeneration patients have a typical disease phenotype. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1224.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age-related macular degeneration (AMD) is partially characterized by retinal pigment epithelial (RPE) cell dysfunction, leading to secondary photoreceptor degeneration. Lack of an appropriate in vitro model that could mimic RPE dysfunction is a major limitation to understanding the mechanisms leading to development of AMD. This study aimed to compare human induced pluripotent stem RPE cells (hiPSC-RPE) derived from dry AMD patients with hiPSC-RPE derived from elderly healthy individuals in both normal conditions and under oxidative stress.

Methods : hiPSCs were derived from erythroblasts or fibroblasts of healthy individuals (N=6, 62 ±17 y/o) and from dry AMD patients (N=6, 77 y/o ± 7). They were differentiated into hRPE cells and characterized by morphology, immunofluorescence, FACS and electronic microscopy. Senescent cells were quantified by β-galactosidase activity in basal condition. Fe-NTA added to the culture media was used to mimic oxidative environment. In vitro concentrations of Fe-NTA were determined to evaluate the toxicity level by MTT test (n=3 per cell lines). Oxidative stress was evaluated by detection of oxidized DCFH-DA (n=3 per cell lines). Lysosomal activity was measured by quantification of Cathepsine D level concentration in both normal and oxidative stress conditions. One-way ANOVA was used for statistical analysis.

Results : Both hiPSC-RPE control and AMD cells expressed β-galactosidase activity in basal condition after 3 weeks at passage 2. Under oxidative stress, cell death was observed from 5 mM in both cell populations but in a higher proportion in hiPSC-RPE AMD (100.6 ± 3.7% versus 89.4 ± 6%, p<0.001). ROS production induced by Fe-NTA treatment was higher in hiPSC-RPE AMD cells (p<0.05). For lysosomal activity, Fe-NTA induced a dose-dependent increase of immature Cathepsine D, which was lower in hiPSC-RPE control cells (p<0.05

Conclusions : Both hiPSC-RPE control and AMD cells have a senescent profile. FeNTA induced a higher reactive oxygen species production and increased cell death in hiPSC-RPE AMD as compared to hiPSC-RPE controls. Functional analysis showed differences in lysosomal process between hiPSC-RPE AMD and hiPSC-RPE control. These findings demonstrate that hiPSC-RPE AMD cells have a typical disease phenotype compared to hiPSC-RPE control cells in a pro-oxidant environment.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×